Clinical trials: Patients With Major Depressive Disorder
Major Depressive Disorder, Recurrent Depressive Disorder
Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression
Major depressive disorders are real public health issues in terms of diagnosis and treatment. Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide risk is important.
- Conditions
- Major Depressive Disorder, Recurrent Depressive Disorder, Bipolar Disorder
- Trial name
- STHYM (NCT01973478)
- Testing
- DBS
- Where
- 5 sites in France
- Volunteers
- 9 people
- Sponsor
- Rennes University Hospital
Unipolar Depression, Major Depressive Disorder (MDD)
Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach.
- Conditions
- Unipolar Depression, Major Depressive Disorder (MDD), Depression
- Trial name
- EMC2FR (NCT06860165)
- Where
- 2 sites in France
- Volunteers
- 98 people
- Sponsor
- Emobot
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly…
- Trial name
- ZEPHIR (NCT00319709)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Finland and 3 more
- Volunteers
- 288 people
- Sponsor
- Sanofi
Autism Spectrum Disorder, Depression
Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)
Depression is a common complication of Autism Spectrum Disorder (ASD): it is four times more prevalent in people with ASD than in the general population.
- Conditions
- Autism Spectrum Disorder, Depression, Major Depressive Episode (MDE)
- Trial name
- DEPASS'R (NCT07258914)
- Testing
- rTMS, rTMS treatment with intermittent Theta Burst (ITBS)
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospital Center Guillaume Régnier
Major Depressive Disorder
Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of semaglutide once-weekly vs. placebo on depressive symptoms in 116 patients with Major Depressive Disorder (MDD) and co-existing…
- Trial name
- SEMAMOOD (NCT07136714)
- Testing
- Semaglutide Injectable Product
- Where
- Denmark
- Volunteers
- 116 people
- Sponsor
- Nordsjaellands Hospital
Major Depressive Disorders
The Effects of Transcranial Magnetic Stimulation on Retina and Choroidal Structures
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMSEYE (NCT06615804)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Depressive Disorder, Major
A Study in Adult Patients With Major Depressive Disorder
The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.
- Trial name
- NCT00795821
- Testing
- LY2216684
- Where
- 37 sites in United States, Argentina and 3 more
- Volunteers
- 495 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Neutralizing Interleukin (IL)-6
The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major Depressive Disorder (MDD) and evidence of…
- Trial name
- NCT07493317
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
A Study of Ketamine in Patients With Treatment-resistant Depression
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
- Trial name
- NCT01627782
- Testing
- Ketamine
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder Patients
Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder
The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive…
- Trial name
- NCT01871974
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Inc
Bipolar Disorder
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.
- Trial name
- NCT00338273
- Testing
- Aripiprazole
- Where
- 8 sites in United States, India
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depression, Dysthymia
Treating Depression Among Low-Income Patients With Cancer
The ADAPt-C collaborative depression care model is designed to: improve depression symptom reduction in the intervention group over the modestly enhanced usual care group of low-income, predominantly Hispanic, patients with…
- Trial name
- ADAPt-C (NCT00565110)
- Testing
- ADAPt-C intervention
- Where
- United States
- Volunteers
- 472 people
- Sponsor
- University of Southern California
Major Depressive Disorder
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01944969
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01377194
- Testing
- Levomilnacipran ER
- Where
- 51 sites in United States, Canada
- Volunteers
- 568 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969709
- Testing
- Levomilnacipran ER
- Where
- 38 sites in United States
- Volunteers
- 724 people
- Sponsor
- Forest Laboratories
Depression
Electrical Stimulation in Patients With Unipolar Major Depression
Double Blinded Randomized Trial of sTNS as adjuvant treatment for Major Unipolar Depressive Disorder. The primary objective is to assess the safety and tolerability of an implantable sTNS of the V1 branch of the trigeminal nerve…
- Trial name
- TREND1 (NCT02239809)
- Testing
- Stimulation of the trigeminal nerve (active stimulation)
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital do Coracao
Major Depressive Disorder
Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients with Recurrent Major Depressive Disorder
- Trial name
- NCT00514865
- Testing
- ONO-2333Ms Experimental 2, ONO-2333Ms Experimental 1
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Ono Pharma USA Inc
Major Depressive Disorder
A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine
The purpose of this study was to investigate the efficacy and safety of antidepressant augmentation with agomelatine in the treatment of patients with depression who did not demonstrate satisfying response to selective serotonin…
- Trial name
- NCT04589143
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Central South University
Bipolar Disorders
A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder
The purpose of this NIS is to obtain data on how AAPs are used in DSM-IV-TR Bipolar I and II Disorder, in the course of a major depressive episode.
- Trial name
- HARMONY (NCT00888264)
- Where
- 45 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Treatment Resistant Depression
Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression
In this study patients with treatment resistant depression, as defined by Harold Sackeim, is subjected to daily sessions, for eight weeks, with Pulsating ElectroMagnetive Treatment (PEMF).
- Trial name
- PEMFII (NCT01353092)
- Testing
- Re5 Pulsating ElectroMagnetic Fields, Re5 Pulsating ElectroMagnetic Fields (PEMF)
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Hillerod Hospital, Denmark